• Many investors are asking whether Novanta's recent share price strength still leaves room for value, or if the stock has already run ahead of itself.
• The stock recently closed at US$155.44, with returns of 11.9% over 7 days, 20.9% over 30 days, 39.9% year to date, 18.3% over 1 year, 13.8% over 5 years, while the 3 year return shows a decline of 6.5%.
• Recent coverage has focused on how the stock's performance fits into broader interest in technology and healthcare focused companies, as investors reassess where they want exposure. This context helps explain why sentiment around Novanta has shifted at the same time as long term return figures remain mixed.
• Simply Wall St currently gives Novanta a valuation score of 0/6. The next sections walk through the standard valuation checks and then finish with a broader framework that can help you interpret these numbers in a more complete way.

Novanta scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Novanta Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return, to arrive at an estimate of what the business might be worth per share right now.

For Novanta, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $65.21 million. Simply Wall St applies analyst estimates where available, then extrapolates beyond that window, leading to projected free cash flow of $158.70 million in 2026 and $180.80 million in 2027. Further out, the model extends those projections through to 2035, discounting each year back to today before aggregating the results.

This process produces an estimated intrinsic value of about $105.06 per share for Novanta, compared with the recent share price of $155.44. On this DCF view, the stock screens as around 48.0% more expensive than the model’s fair value estimate. This points to a rich valuation based purely on these cash flow assumptions.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Novanta may be overvalued by 48.0%. Discover 47 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Novanta Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It links directly to the bottom line, which is what ultimately supports a share price over time.

What counts as a "normal" P/E depends on how fast earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually supports a lower one.

Novanta currently trades on a P/E of 103.04x. That is well above the Electronic industry average of 28.12x and also above the peer group average of 56.97x. Simply Wall St’s Fair Ratio is 54.18x, which is its proprietary view of what a reasonable P/E could be for Novanta, given factors such as earnings growth, profit margins, industry, market cap and company specific risks.

This Fair Ratio is more tailored than a simple comparison with peers or the wider industry, because it adjusts for the company’s own characteristics rather than assuming all companies should trade on the same multiple. Comparing the Fair Ratio of 54.18x with the current P/E of 103.04x suggests the stock is trading well above this framework’s estimate of fair value.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Novanta Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Think of a Narrative as your own clear story for Novanta that links what you believe about its markets, margins and earnings power to a financial forecast, a fair value per share, and then a simple comparison with today’s price. All of this is inside an easy tool on Simply Wall St’s Community page that millions of investors use. Narratives for Novanta can range from a more optimistic view that its exposure to robotics, automation and medical devices supports higher earnings and a fair value near the US$157 consensus target, through to a more cautious view that focuses on risks like reliance on acquisitions, trade disruptions and margin pressure and therefore points to a lower fair value. Each Narrative is automatically refreshed as new earnings, news or guidance arrives, so you can quickly see whether your story, and your view on whether the stock looks expensive or cheap versus your own fair value, still holds up.

Do you think there's more to the story for Novanta? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.